Megan E Baldwin
Overview
Explore the profile of Megan E Baldwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wykoff C, Jackson T, Price C, Baldwin M, Leitch I, Slakter J
Ophthalmic Surg Lasers Imaging Retina
. 2025 Feb;
:1-10.
PMID: 39999360
Background And Objective: The purpose of this study was to evaluate the angiographic predictors of response to the anti-vascular endothelial growth factor-C/-D agent, sozinibercept. Patients And Methods: Prespecified and post...
2.
Boyer D, Steinle N, Pearlman J, Stone C, Crawford C, Gupta S, et al.
Transl Vis Sci Technol
. 2024 Dec;
13(12):32.
PMID: 39699889
Purpose: Sozinibercept inhibits vascular endothelial growth factors (VEGFs) C and D. This study evaluated outcomes following switching from anti-VEGF-A monotherapy to intravitreal injections of three dose levels of sozinibercept in...
3.
Leitch I, Gerometta M, Eichenbaum D, Finger R, Steinle N, Baldwin M
Ophthalmol Ther
. 2024 Jun;
13(7):1857-1875.
PMID: 38824253
The development of treatments targeting the vascular endothelial growth factor (VEGF) signaling pathways have traditionally been firstly investigated in oncology and then advanced into retinal disease indications. Members of the...
4.
Jackson T, Slakter J, Buyse M, Wang K, Dugel P, Wykoff C, et al.
Ophthalmology
. 2023 Feb;
130(6):588-597.
PMID: 36754174
Purpose: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of...
5.
Dugel P, Boyer D, Antoszyk A, Steinle N, Varenhorst M, Pearlman J, et al.
Ophthalmol Retina
. 2020 Jan;
4(3):250-263.
PMID: 31924544
Purpose: OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab...
6.
Woollard D, Opeskin K, Coso S, Wu D, Baldwin M, Williams E
Prostate
. 2012 Oct;
73(6):563-72.
PMID: 23038639
Background: Prostate cancer disseminates to regional lymph nodes, however the molecular mechanisms responsible for lymph node metastasis are poorly understood. The vascular endothelial growth factor (VEGF) ligand and receptor family...
7.
Karnezis T, Shayan R, Caesar C, Roufail S, Harris N, Ardipradja K, et al.
Cancer Cell
. 2012 Feb;
21(2):181-95.
PMID: 22340592
Lymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are secreted by some primary tumors. We identified regulation of PGDH, the key enzyme in prostaglandin catabolism, in...
8.
Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen M, Baldwin M, et al.
Mol Cell Biol
. 2008 Jun;
28(15):4843-50.
PMID: 18519586
Lymphatic vessels play an important role in the regulation of tissue fluid balance, immune responses, and fat adsorption and are involved in diseases including lymphedema and tumor metastasis. Vascular endothelial...
9.
Shojaei F, Wu X, Malik A, Zhong C, Baldwin M, Schanz S, et al.
Nat Biotechnol
. 2007 Aug;
25(8):911-20.
PMID: 17664940
Vascular endothelial growth factor (VEGF) is an essential regulator of normal and abnormal blood vessel growth. A monoclonal antibody (mAb) that targets VEGF suppresses tumor growth in murine cancer models...
10.
Stacker S, Farnsworth R, Karnezis T, Shayan R, Smith D, Paavonen K, et al.
Novartis Found Symp
. 2007 May;
281:38-43.
PMID: 17534064
The lymphatic network functions to return fluid, cells and macromolecules to the circulation. Recent characterization of growth factors that control the growth and development of the lymphatics, and markers which...